Brain-computer interfaces span a wide spectrum from fully implanted intracortical arrays to wearable EEG headsets. Each approach makes a different tradeoff between signal quality and surgical risk. Neuralink's N1 implant records single-neuron spikes from 1,024 electrodes embedded in brain tissue. Synchron's Stentrode threads through a blood vessel with no brain surgery. Precision Neuroscience places a thin-film ECoG array on the cortical surface through a minimally invasive slit. Kernel and OpenBCI offer non-invasive headsets with zero surgical risk but far lower resolution. This page compares all four BCI modalities across every dimension that matters: signal quality, electrode count, surgical approach, reversibility, FDA status, and clinical outcomes.
| Spec | Intracortical (penetrating) | Endovascular | ECoG (electrocorticography) | Non-invasive (EEG/fNIRS) |
|---|---|---|---|---|
| Category | Invasive | Minimally invasive | Invasive (surface) | Non-invasive |
| Lead Company / Device | Neuralink (N1) | Synchron (Stentrode) | Precision Neuroscience (Layer 7) | Kernel (Flow), OpenBCI (various) |
| Electrode Count | 1,024 | 16 | Up to 4,096 | 52 (Kernel Flow) / 8-16 (OpenBCI) |
| Signal Type | Single-unit spikes, multi-unit activity | Local field potentials, high-gamma | ECoG, high-gamma, local field potentials | EEG scalp potentials, fNIRS hemodynamics |
| Surgical Approach | Craniotomy + robotic thread insertion | Catheter via jugular vein (no brain surgery) | Minimally invasive slit craniotomy | None (wearable headset) |
| Procedure Time | ~2 hours | ~20 minutes | ~30 minutes | N/A |
| Reversibility | Difficult (threads embedded in cortex) | Potentially reversible (stent in vessel) | Reversible (surface array, no penetration) | Fully reversible (no implant) |
| Signal Quality | Highest (direct neuron contact) | Moderate (through vessel wall) | High (direct cortical surface) | Low (attenuated through skull) |
| FDA Status | IDE (PRIME study) | Breakthrough Device Designation | Investigational | Consumer / research use |
| Patients Implanted | 21 (as of Dec 2025) | 10 (SWITCH + COMMAND) | 7+ (acute intraoperative studies) | N/A (consumer devices) |
| Best For | Maximum bandwidth, fine motor control | Low surgical risk, broad accessibility | High-density cortical mapping, reversible | Research, consumer neurotech, zero risk |
Signal quality is the primary differentiator between BCI approaches. The closer electrodes are to neurons, the higher the signal-to-noise ratio and the more information can be decoded per second. This determines what a BCI user can actually do: type speed, cursor precision, number of controllable degrees of freedom, and potential for sensory feedback.
The invasive vs non-invasive BCI debate is not a winner-take-all contest. Each approach occupies a distinct position on the signal quality vs surgical risk spectrum. Intracortical BCIs like Neuralink deliver unmatched bandwidth for patients with severe paralysis. Endovascular BCIs like Synchron offer a safer path for patients who cannot or will not undergo brain surgery. ECoG arrays from Precision Neuroscience provide high-density recording with reversibility. Non-invasive devices serve the vast consumer and research market where implant surgery is not an option.
The BCI market is large enough for all four modalities to thrive. The question is not which approach wins, but which approach is right for which patient and use case.
Data sourced from ClinicalTrials.gov, FDA device databases, peer-reviewed publications in Nature, JAMA Neurology, and Journal of Neural Engineering, and verified company disclosures. Signal quality comparisons based on published electrophysiology benchmarks. Last verified: March 2026.